NCT05793801 Study of the Impact of Frequency of Changing PICCline Dressings in Patients With Acute Leukemia
| NCT ID | NCT05793801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nīmes |
| Condition | Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-06-06 |
| Primary Completion | 2027-06-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-06-06 with a primary completion date of 2027-06-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Peripherally Inserted Central Catheters have been widely used for many years for the administration of chemotherapy to patients with cancer. However, its use entails significant infectious complications and high risks of death.The hypothesis is that increasing the rate of PICCline dressing changes will reduce the occurrence of catheter-related infections.
Eligibility Criteria
Inclusion Criteria: * Patient with a diagnosis of acute myeloblastic leukemia. * Patient going on intensive induction chemotherapy (causing a "high risk" situation of severe infection defined as profound neutropenia ( Polymorphonuclear neutrophil count \<500/mm3) and lasting (\>7 days). * Patients who have had a PICCline placed within the last 24 hours or who require a PICCline placement as part of their hospitalization under optimal hygiene and asepsis conditions. * Patient housed in a protected environment (flow chamber or Plasmair®). * Patient who has given free and informed consent. * Patient affiliated or beneficiary of a health insurance plan. * Adult patient (≥18 years old). Exclusion Criteria: * Patient with PICCline placed during a previous hospitalization. * Patient in an exclusion period determined by another study. * Patient under court protection, guardianship or curatorship. * Patient unable to give consent. * Patient for whom it is impossible to give informed information.
Contact & Investigator
Julie LASSALLE, Mme.
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Nīmes
Frequently Asked Questions
Who can join the NCT05793801 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05793801 currently recruiting?
Yes, NCT05793801 is actively recruiting participants. Contact the research team at Eric.jourdan@chu-nimes.fr for enrollment information.
Where is the NCT05793801 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT05793801 clinical trial?
NCT05793801 is sponsored by Centre Hospitalier Universitaire de Nīmes. The principal investigator is Julie LASSALLE, Mme. at Centre Hospitalier Universitaire de Nīmes. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.